Patents Examined by Brian Hartnett
-
Patent number: 11970545Abstract: A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. The ligand that binds a protein associated with a TCR complex is UCHT1 with a Y182T mutation. Engineering T cells with this novel receptor engenders antigen specific activation of numerous T cell functions, including cytokine production, degranulation and cytolysis.Type: GrantFiled: March 22, 2023Date of Patent: April 30, 2024Assignee: McMaster UniversityInventors: Christopher W. Helsen, Jonathan Bramson, Anna Dvorkin-Gheva, Galina F. Denisova, Ksenia Bezverbnaya, Kenneth Anthony Mwawasi
-
Patent number: 11957717Abstract: The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.Type: GrantFiled: April 9, 2021Date of Patent: April 16, 2024Assignee: HRAIN BIOTECHNOLOGY CO., LTD.Inventors: Fei Huang, Tao Peng, Xuemei Zou, Pinglei Liu, Dachun Liu, Hui Huang
-
Patent number: 11951130Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.Type: GrantFiled: March 1, 2021Date of Patent: April 9, 2024Assignee: Eutilex Co., Ltd.Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
-
Patent number: 11945876Abstract: Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.Type: GrantFiled: June 15, 2022Date of Patent: April 2, 2024Assignees: Instil Bio (UK) Limited, Instil Bio, Inc.Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou
-
Patent number: 11897966Abstract: Disclosed herein are anti-mesothelin antibodies and antigen-binding fragments, chimeric antigen receptors (“CARs”) having these anti-mesothelin antibodies and antigen-binding fragments (“mesothelin CARs”) and genetically modified immune effector cells having such mesothelin CARs. Polynucleotides encoding the anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. Compositions comprising anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. The present disclosure also relates to uses of the anti-mesothelin antibodies and antigen-binding fragments and genetically modified immune effector cells having such mesothelin CARs in cancer treatment.Type: GrantFiled: December 6, 2022Date of Patent: February 13, 2024Assignee: UTC THERAPEUTICS (SHANGHAI) CO., LTD.Inventors: Yangbing Zhao, Gengzhen Zhu, Xiaojun Liu
-
Patent number: 11898165Abstract: Provided herein are engineered host cells suitable for expression of functional T cell receptors (TCR) and methods of using these cells to identify TCRs that specifically bind to a desired peptide-major histocompatibility complex (MHC) complex.Type: GrantFiled: September 9, 2016Date of Patent: February 13, 2024Assignee: MiNK Therapeutics, Inc.Inventors: Marc Van Dijk, Volker Seibert, Robert Benjamin Stein
-
Patent number: 11896616Abstract: The present invention relates to genetically engineered cell populations derived from an immortalised/cancerous cell that do not express MHC class I molecules but that are modified to express membrane-bound IL-15, membrane-bound 4-1 BBL ligand, and at least one other membrane bound molecule, such as an interleukin or anti-CD3 antibody. The co-culture of said cells with a population of immune cells results in the activation and expansion of at least one subpopulation of immune cells. Expanded populations of NK cells derived from the co-culture of a mixed cell culture with the stimulatory cell lines may be used in methods of treating cancer or an infectious disease. In a separate embodiment, a plurality of nucleic acids for use in preparing the engineered cell population are provided.Type: GrantFiled: March 27, 2018Date of Patent: February 13, 2024Assignee: National University of SingaporeInventors: Takahiro Kamiya, Dario Campana
-
Patent number: 11883430Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.Type: GrantFiled: November 8, 2017Date of Patent: January 30, 2024Assignee: MUSC Foundation for Research DevelopmentInventors: Shikhar Mehrotra, Shilpak Chatterjee
-
Patent number: 11851499Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.Type: GrantFiled: June 10, 2020Date of Patent: December 26, 2023Assignee: BioAtla, Inc.Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
-
Patent number: 11851460Abstract: Provided herein are antibody molecules that bind specifically to Programmed cell death 1 (PD1) and related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.Type: GrantFiled: November 2, 2020Date of Patent: December 26, 2023Assignee: ULTRAHUMAN EIGHT LIMITEDInventor: William James Jonathan Finlay
-
Patent number: 11779603Abstract: Disclosed herein are T cell receptors (TCRs) capable of binding an antigen expressed by renal cell carcinoma cells. In some examples, the TCRs include an ? chain (such as SEQ ID NO: 2) and a ? chain (such as SEQ ID NO: 3). Also disclosed herein are vectors including nucleic acids encoding the disclosed TCR ? and/or ? chains. Further disclosed are modified T cells expressing the TCRs. In some examples, the modified T cells are prepared by transducing T cells with a vector including nucleic acids encoding the TCR ? chain and the TCR ? chain. In some embodiments, methods include treating a subject with RCC, by obtaining a population of T cells, transducing the population of T cells with a vector including a nucleic acids encoding the TCR ? chain and the TCR ? chain, and administering a composition comprising the modified T cells to the subject.Type: GrantFiled: June 30, 2017Date of Patent: October 10, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Loyola University of ChicagoInventors: Richard W. Childs, Michael I. Nishimura, Elena A. Cherkasova
-
Patent number: 11759480Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.Type: GrantFiled: July 6, 2020Date of Patent: September 19, 2023Assignees: ENDOCYTE, INC., PURDUE RESEARCH FOUNDATIONInventors: Philip Stewart Low, Haiyan Chu, Yong Gu Lee, Yingjuan J. Lu, Christopher Paul Leamon, Leroy W Wheeler, II
-
Patent number: 11747345Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.Type: GrantFiled: February 19, 2018Date of Patent: September 5, 2023Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: David E. Gerber, Edward Wakeland, Quan Li, Saad Khan, Jason Y. Park, Xin Luo, Yang Xie
-
Patent number: 11718658Abstract: Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.Type: GrantFiled: March 3, 2020Date of Patent: August 8, 2023Assignee: MiNK Therapeutics, Inc.Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Alessandra Franchino, Sébastien Lalevée, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf
-
Patent number: 11712469Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.Type: GrantFiled: April 13, 2020Date of Patent: August 1, 2023Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Christopher C. Kloss, Michel Sadelain
-
Patent number: 11707486Abstract: Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.Type: GrantFiled: July 5, 2019Date of Patent: July 25, 2023Assignees: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: In Pyo Choi, Tae-Don Kim, Su Ui Lee, Sooyun Lee, Junho Chung, Ki-Hyun Kim, Hyori Kim
-
Patent number: 11701385Abstract: Embodiments relate to a modified cell comprising an antigen binding molecule, and the expression and/or function of one or more genes in the modified cell has been enhanced or reduced or eliminated. The one or more genes include CXCR3, SLC1A3, YAP, TIGIT, S1P1, and IL-35. In embodiments, the cell is a T cell, a dendritic cell, a NK cell, or a macrophage cell. In embodiments, the antigen binding molecule comprises a chimeric antigen receptor (CAR) and/or the second antigen binding molecule is a T Cell Receptor (TCR).Type: GrantFiled: August 29, 2019Date of Patent: July 18, 2023Assignee: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao, Zhao Wu
-
Patent number: 11643472Abstract: A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. The ligand that binds a protein associated with a TCR complex is UCHT1 with a Y182T mutation. Engineering T cells with this novel receptor engenders antigen specific activation of numerous T cell functions, including cytokine production, degranulation and cytolysis.Type: GrantFiled: October 12, 2018Date of Patent: May 9, 2023Assignee: McMaster UniversityInventors: Christopher W. Helsen, Jonathan Bramson, Anna Dvorkin-Gheva, Galina F. Denisova, Ksenia Bezverbnaya, Kenneth Anthony Mwawasi
-
Patent number: 11643447Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.Type: GrantFiled: June 1, 2022Date of Patent: May 9, 2023Assignee: Shattuck Labs, Inc.Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
-
Patent number: 11629199Abstract: The present application relates to specific binding members that bind carbonic anhydrase IX (CAIX). In particular, the present application relates to the treatment, diagnosis and detection of tumours, e.g. solid tumours, using specific binding members that bind CAIX. The specific binding member may be conjugated to a biocidal or cytotoxic molecule, or to a detectable label.Type: GrantFiled: December 19, 2018Date of Patent: April 18, 2023Inventors: Laura Gualandi, Sarah Wulhfard, Francesca Pretto, Catherine Pemberton-Ross, Alessandra Villa, Roberto De Luca